NR3C2 and chronic kidney disease: It is noteworthy to mention that, in a recent study involving patients at risk for HF with CKD and T2DM, irrespective of their HF history, the selective MR antagonist finerenone, when added to the maximally tolerated dose of RAASis, demonstrated improvement in CV and kidney outcomes [68].